India's Largest Database on New Projects
Bafna Pharma to strengthen presence in haematinic drug mkt
14 April 2011: Bafna Pharmaceuticals, which acquired haematinic drug Raricap from Johnson & Johnson (J&J)-affiliate NR Jet recently, is planning to strengthen its presence in the segment.
The company is in the process of acquiring around 14 haematinic drugs, used to increase haemoglobin levels in blood, with an investment of around Rs 25 crore. The investment will be from equity from strategic partners and debt.
Bafna has been manufacturing Raricap on contract for J&J for around two years. It discontinued the manufacturing deal almost six months ago after the product underwent some formulation changes. J&J has not been promoting the drug for past few years, which affected its market performance.
Source: Business standard